X

Drug Profile

IDD 5

Alternative Names: Collidem; IDD-5

Latest Information Update: 22 Feb 2010

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IDM Pharma
Developer Takeda America Holdings
Class Cancer vaccines; Dendritic cell vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Colorectal cancer

Most Recent Events

25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
07 Feb 2006 Clinical data from a media release have been added to the adverse events and Cancer immunogenicity section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com